| Rank |
Title |
Year |
PubWeight™‹?› |
|
1
|
CpG still rocks! Update on an accidental drug.
|
2012
|
1.55
|
|
2
|
The interaction of telomeric DNA and C-myc22 G-quadruplex with 11 natural alkaloids.
|
2012
|
1.49
|
|
3
|
Oligonucleotide delivery by nucleofection does not rescue the reduced proliferation phenotype of gene-edited cells.
|
2012
|
1.40
|
|
4
|
Uniqueness, advantages, challenges, solutions, and perspectives in therapeutics applying RNA nanotechnology.
|
2012
|
1.19
|
|
5
|
Long non-coding RNAs: challenges for diagnosis and therapies.
|
2013
|
1.16
|
|
6
|
Rational truncation of an RNA aptamer to prostate-specific membrane antigen using computational structural modeling.
|
2011
|
1.16
|
|
7
|
Nucleotide bias observed with a short SELEX RNA aptamer library.
|
2011
|
1.15
|
|
8
|
Chemical modification study of antisense gapmers.
|
2012
|
1.13
|
|
9
|
A locked nucleic acid oligonucleotide targeting microRNA 122 is well-tolerated in cynomolgus monkeys.
|
2012
|
1.12
|
|
10
|
Argonaute and the nuclear RNAs: new pathways for RNA-mediated control of gene expression.
|
2012
|
1.10
|
|
11
|
Developing microRNA therapeutics: approaching the unique complexities.
|
2012
|
1.10
|
|
12
|
Polymers in small-interfering RNA delivery.
|
2011
|
1.09
|
|
13
|
RNA sequencing: platform selection, experimental design, and data interpretation.
|
2012
|
1.07
|
|
14
|
FDA Approves Eteplirsen for Duchenne Muscular Dystrophy: The Next Chapter in the Eteplirsen Saga.
|
2016
|
1.07
|
|
15
|
In vitro selection of RNA aptamer and specific targeting of ErbB2 in breast cancer cells.
|
2011
|
1.05
|
|
16
|
Phosphorothioates, essential components of therapeutic oligonucleotides.
|
2014
|
1.04
|
|
17
|
Co-injection of a targeted, reversibly masked endosomolytic polymer dramatically improves the efficacy of cholesterol-conjugated small interfering RNAs in vivo.
|
2012
|
1.01
|
|
18
|
A chemical view of oligonucleotides for exon skipping and related drug applications.
|
2013
|
1.00
|
|
19
|
Digital quantitation of potential therapeutic target RNAs.
|
2013
|
0.99
|
|
20
|
Long-term systemic administration of unconjugated morpholino oligomers for therapeutic expression of dystrophin by exon skipping in skeletal muscle: implications for cardiac muscle integrity.
|
2011
|
0.98
|
|
21
|
Long non-coding RNA targeting and transcriptional de-repression.
|
2013
|
0.98
|
|
22
|
Nanoparticle delivery of antisense oligonucleotides and their application in the exon skipping strategy for Duchenne muscular dystrophy.
|
2014
|
0.97
|
|
23
|
Antiproliferative activity of novel thiopyran analogs on MCF-7 breast and HCT-15 colon cancer cells: synthesis, cytotoxicity, cell cycle analysis, and DNA-binding.
|
2012
|
0.97
|
|
24
|
Research progress of RNA quadruplex.
|
2011
|
0.96
|
|
25
|
Extensive and prolonged restoration of dystrophin expression with vivo-morpholino-mediated multiple exon skipping in dystrophic dogs.
|
2012
|
0.95
|
|
26
|
Preclinical evaluation of the toxicological effects of a novel constrained ethyl modified antisense compound targeting signal transducer and activator of transcription 3 in mice and cynomolgus monkeys.
|
2013
|
0.95
|
|
27
|
Skipping multiple exons of dystrophin transcripts using cocktail antisense oligonucleotides.
|
2013
|
0.94
|
|
28
|
Targeted p21WAF1/CIP1 activation by RNAa inhibits hepatocellular carcinoma cells.
|
2012
|
0.94
|
|
29
|
Degradation of nuclease-stabilized RNA oligonucleotides in Mycoplasma-contaminated cell culture media.
|
2012
|
0.92
|
|
30
|
Systemic delivery of a Peptide-linked morpholino oligonucleotide neutralizes mutant RNA toxicity in a mouse model of myotonic dystrophy.
|
2013
|
0.92
|
|
31
|
Potent antibacterial antisense peptide-peptide nucleic acid conjugates against Pseudomonas aeruginosa.
|
2012
|
0.91
|
|
32
|
Hepatotoxic potential of therapeutic oligonucleotides can be predicted from their sequence and modification pattern.
|
2013
|
0.91
|
|
33
|
Cellular uptake and intracellular trafficking of oligonucleotides: implications for oligonucleotide pharmacology.
|
2014
|
0.90
|
|
34
|
The mix of two worlds: non-coding RNAs and hormones.
|
2012
|
0.90
|
|
35
|
Exploring the effect of sequence length and composition on allele-selective inhibition of human huntingtin expression by single-stranded silencing RNAs.
|
2014
|
0.90
|
|
36
|
Characterization of target mRNA reduction through in situ RNA hybridization in multiple organ systems following systemic antisense treatment in animals.
|
2013
|
0.90
|
|
37
|
Preparation of single-stranded DNA from PCR products with streptavidin magnetic beads.
|
2011
|
0.89
|
|
38
|
Selection of an antiviral RNA aptamer against hemagglutinin of the subtype H5 avian influenza virus.
|
2011
|
0.89
|
|
39
|
Aptamer-mediated delivery of splice-switching oligonucleotides to the nuclei of cancer cells.
|
2012
|
0.88
|
|
40
|
Structural diversity repertoire of gene silencing small interfering RNAs.
|
2011
|
0.87
|
|
41
|
Aptamer-mediated delivery of chemotherapy to pancreatic cancer cells.
|
2012
|
0.87
|
|
42
|
Fluorogenic RNA nanoparticles for monitoring RNA folding and degradation in real time in living cells.
|
2012
|
0.87
|
|
43
|
Short double-stranded RNA with immunostimulatory activity: sequence dependence.
|
2012
|
0.86
|
|
44
|
Activation of the miR-17 family and miR-21 during murine kidney ischemia-reperfusion injury.
|
2013
|
0.86
|
|
45
|
Peptide conjugated phosphorodiamidate morpholino oligomers increase survival of mice challenged with Ames Bacillus anthracis.
|
2012
|
0.86
|
|
46
|
Immune activation and target organ damage are consequences of hydrodynamic treatment but not delivery of naked siRNAs in mice.
|
2011
|
0.86
|
|
47
|
Immunostimulatory potential of silencing RNAs can be mediated by a non-uridine-rich toll-like receptor 7 motif.
|
2011
|
0.86
|
|
48
|
RNA interference trigger variants: getting the most out of RNA for RNA interference-based therapeutics.
|
2012
|
0.86
|
|
49
|
In vitro selection of modified RNA aptamers against CD44 cancer stem cell marker.
|
2013
|
0.86
|
|
50
|
Nucleic acid aptamers against biotoxins: a new paradigm toward the treatment and diagnostic approach.
|
2012
|
0.85
|